For clinicians, it highlights the growing importance of identifying HER2-low status, guiding treatment decisions and patient stratification, HER-2 immunohistochemical testing should employ two distinct antibody reagents on breast cancer specimens. This evidence concerns the gene ERBB2 and breast carcinoma.